Clinical use of CAR T-cells in treating acute lymphoblastic leukemia
Transfusion and Apheresis Science, cilt.62, sa.2, 2023 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Derleme
- Cilt numarası: 62 Sayı: 2
- Basım Tarihi: 2023
- Doi Numarası: 10.1016/j.transci.2023.103666
- Dergi Adı: Transfusion and Apheresis Science
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, Biotechnology Research Abstracts, MEDLINE
- Anahtar Kelimeler: CAR T -cell, Clinical use, Relapse, Refractory, Acute lymphoblastic leukemia
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment landscape for adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). However CAR T-cell therapy of R/R T-ALL has unique challenges, such as the lack of specific tumor antigens, cell fratricide and T cell aplasia, in comparison with that of R/R B-ALL. Despite promising therapeutic outcomes in R/R B-ALL, application of this therapy is limited by high relapse rates and immunological toxicities. Recent studies suggest patients who underwent allogeneic hematopoietic stem cell transplantation post-CAR T-cell therapy would achieve durable remission and better survival, but this remains controversial. Herein, I briefly review published data on the clinical use of CAR T-cells in treating ALL.